ADJUVANTICITY OF A NOVEL NANOSTRUCTURE FROM ASCORBYL PALMITATE REQUIRES THE ADAPTOR PROTEIN MYD88

SANCHEZ-VALLECILLO,MF; CHIODETTI, A; ULLO, G; PALMA, S; ALLEMANDI, D; MORÓN, G; PISTORESI, MC; MALETTO B

Los Cocos. Cordoba

Congreso; LXI Reunión de la Sociedad Argentina de Inmunología.; 2013

Sociedad Argentina de Inmunologia

CpG-ODN has successfully been used as adjuvant but unfortunately has a limited bioavailability; in order to improve it we formulated CpG-ODN in a nanostructure from 6-O-ascorbyl palmitate (Coa-ASC16). We previously showed that this strategy improves the adjuvant activity of CpG-ODN and that Coa-ASC16 promotes an inflammatory response at the injection site and also, it has adjuvant activity per se. In order to decipher the mechanism involved, we assessed the contribution of the adaptor protein MyD88 to the adjuvant activity of Coa-ASC16. MyD88-/- or WT mice received three immunizations (day 0, 7 and 15) with OVA (60μg/mice/dose) or OVA/Coa-ASC16. OVA-specific IgG1 (2.5±0.4 vs. 4.6±0.1), IgG2a (0.2±0.2 vs. 1.6±0.2) and IFN-γ (pg/ml: not detected vs. 931±223) were reduced in OVA/Coa-ASC16 MyD88-/- mice compared with WT controls (p